A strong clinical result can create real momentum for a pharmaceutical product, but it’s only one part of the approval story. Regulators also need confidence that the product can be made consistently, tested properly and supplied at the required quality. That’s where Chemistry, Manufacturing and Controls, or CMC, comes in.
For both the US Food and Drug Administration (FDA) and Australia’s Therapeutic Goods Administration (TGA), CMC plays a major role in determining whether a product is ready to move through development and, ultimately, reach the market.
It’s not simply a section of the regulatory dossier. It’s the body of evidence that shows a medicine is understood, controlled and capable of being manufactured reliably.
What Does CMC Actually Cover?
CMC brings together the technical information behind a pharmaceutical product. It explains what the product contains, how it’s made, how it’s tested, how its quality is controlled and how long it’s expected to remain stable. Depending on the product and its stage of development, this may include:
- Drug substance and drug product information
- Formulation development
- Raw material and excipient controls
- Manufacturing processes
- In-process controls
- Product specifications
- Analytical methods and validation
- Impurity and degradation profiles
- Packaging and container closure systems
- Stability data
- Storage conditions
- GMP manufacturing and testing arrangements
These areas are closely linked. A formulation change may affect stability. A manufacturing change may alter dissolution, particle size or product uniformity. A packaging change may influence moisture protection, light exposure or extractables and leachables. That’s why CMC works best when it’s treated as one connected program rather than a series of separate tasks.
Why CMC Matters for FDA and TGA Approval
The FDA and TGA aren’t only assessing whether a product worked in a clinical trial. They also need to know that the product supplied to future patients will be representative of the one used during development. In other words, can the same medicine be made again and again, to the same standard? That confidence depends on a well-developed manufacturing process, suitable analytical methods, justified specifications, appropriate stability data and a clear quality control strategy.
A finished batch can’t simply be tested at the end and declared acceptable; quality needs to be built into the product and process from the beginning. Regulators will typically want to understand:
- Has the product been properly characterised?
- Is the manufacturing process controlled?
- Are critical quality attributes understood?
- Are the analytical methods fit for purpose?
- Are impurities and degradation products controlled?
- Does the stability data support the proposed shelf life?
- Are the manufacturing and testing sites GMP compliant?
- Is there a clear link between clinical and commercial batches?
When the answers aren’t clear, approval timelines can quickly stretch out. CMC issues can delay approval even when the clinical data is positive. Common problems include incomplete process validation, weak justification of specifications, unresolved impurity concerns, inadequate stability data and poor comparability between development and commercial batches.
These aren’t minor paperwork gaps. They go directly to whether regulators can trust the quality and consistency of the proposed product.
What FDA and TGA Reviewers Look for
CMC expectations increase as a product moves through development. During early clinical stages, the formulation, process and analytical methods may still be evolving. Regulators recognise that. The information provided needs to be appropriate for the product’s stage, rather than fully commercial from day one.
That said, early-stage development isn’t a free pass. The available CMC package still needs to support patient safety, product quality and reliable clinical supply. As development progresses, the level of detail and supporting evidence needs to grow with it.
By the time a product reaches a marketing application, regulators will expect a much more mature and consistent package. The dossier needs to clearly explain:
- What the product is
- How it’s manufactured
- Which process parameters are controlled
- How the product is tested
- Why the proposed specifications are appropriate
- How impurities are managed
- How the packaging protects the product
- What supports the proposed shelf life and storage conditions
- How commercial manufacture relates to the batches used during development
GMP compliance is also central to both FDA and TGA approval. The relevant manufacturing, packaging, testing and release activities need to be performed within appropriate quality systems. A technically strong dossier can still run into trouble if manufacturing-site readiness or GMP evidence isn’t in place.
While FDA and TGA expectations are closely aligned, the submission process isn’t completely interchangeable. Each regulator has its own administrative requirements, GMP evidence expectations and market-specific considerations.
Differences in manufacturing sites, packaging, labelling, storage conditions or batch release arrangements may also need to be addressed. The most efficient approach is to build a strong common CMC package, then account for regional requirements early rather than trying to retrofit them at submission stage.
Where CMC Programs Tend to Go Wrong
Most CMC problems don’t suddenly appear during regulatory review… they usually begin much earlier.
- Analytical methods may be developed too late.
- Stability studies may start before the formulation or packaging is final.
- A process that works at laboratory scale may struggle during scale-up.
- Clinical material may be produced using a process that’s difficult to replicate commercially.
Sometimes the issue is less about the science and more about timing. For example, a late change to the formulation, manufacturing site or packaging system can affect stability data, method validation, batch comparability and the regulatory submission itself. A change that appears straightforward in isolation may have consequences across the entire CMC program.
Documentation can also become a problem. If development decisions aren’t recorded clearly at the time, teams may later struggle to explain why a formulation, specification or manufacturing parameter was selected. The underlying work may be sound, but the dossier still needs to show the scientific reasoning behind it.
The most effective CMC programs keep formulation, analytical development, manufacturing, stability, quality and regulatory planning connected from the start.
Building a Stronger Path to Approval
A successful CMC strategy doesn’t need to lock in every decision on day one… but it does need to anticipate what’ll be required later. That starts with a clear understanding of the intended product. Dosage form, strength, route of administration, release profile, packaging, storage and shelf-life goals should all inform the development plan.
Analytical methods also need to be considered early. They’re not just tools for final release testing; they help development teams understand the formulation, monitor impurities, evaluate process changes and study how the product behaves over time. Scale-up should be part of the conversation from the beginning as well. A formulation or process may work well in the laboratory but behave differently when batch size, equipment or manufacturing conditions change.
Stability studies should be designed strategically, using a formulation, process and packaging configuration that’ll produce meaningful data for later stages. Most importantly, each part of the program should support the same product story. The manufacturing process, analytical methods, specifications, stability data and regulatory strategy all need to make sense together.
The goal isn’t to generate the largest possible volume of data. It’s to generate the right evidence, at the right stage, in a form that supports a clear and defensible submission.
Supporting CMC development from early stage to submission
PharmSky supports pharmaceutical companies across the CMC pathway, from early formulation and analytical development through to clinical trial manufacturing, stability testing, GMP storage and regulatory preparation. Our integrated team brings together formulation scientists, analytical specialists, engineers, quality professionals and regulatory experts under one roof.
Why does this matter? Because CMC activities rarely sit in isolation. A decision made during formulation development may affect manufacturing, analytical testing, packaging, stability and the final regulatory strategy. By connecting these areas early, PharmSky helps clients identify risks sooner, reduce unnecessary handovers and build a stronger technical package for FDA, TGA and international submissions.
The strongest programs don’t leave it until submission time. They build quality, manufacturability and regulatory readiness into the product from the beginning.
